10 May Aquaporin broadens business with new subsidiary

Aquaporin > News > News > Aquaporin broadens business with new subsidiary


In the beginning of 2016, Aquaporin A/S invested in Golgi ApS, a start-up company that is to upscale and manufacture aquaporin proteins in kilo gram scale for Aquaporin A/S.

Golgi ApS will be located in our new headquarters and will be fully integrated into Aquaporin’s organization and day-to-day operations.

Golgi is co-founded in collaboration with professor Per Amstrup and partially financed by Aquaporin A/S. Furthermore, Golgi receives co-funding from the Danish Innovation Foundation for development activities since it is an integrated part of the IBISS program.

Aquaporin Production Focus
The overall focus area for Golgi ApS is to secure supply of aquaporin proteins for large scale membrane production in Aquaporin A/S. This will contribute significantly in further strengthening the supply chain and support our growth.
The transition from production of milli-grams to kilo grams of aquaporin protein requires that Golgi ApS installs a dedicated aquaporin production facility including bioreactors and several downstream processing units. The plan is to setup a highly productive facility with the flexibility to produce new aquaporin molecules on a regular basis. That way, Golgi ApS optimally supports Aquaporin business and R&D that continuously strive to develop our product portfolios to new industries.

Experienced management
“In Golgi we are very pleased with the funding from IBISS and with the kick-start we are getting from having Aquaporin A/S as lead investor, strategic partner, and customer. We have gathered a very experienced team, who will work very hard to ensure that we reach our production goals. The plan is to deliver the first amounts of Aquaporin this year, so no doubt we have high ambitions! But we are looking very much forward to this journey together with Aquaporin A/S”, says CEO, Torsten Bak Regueira.

Torsten Bak Regueira,CEO in Golgi, started April 1st 2016 and brings broad-based experience from R&D and management. Torsten has previously been part of starting up the biotech company MycoTeQ A/S. Furthermore, Torsten Bak Regueira holds ten years of experience from three different positions in Novozymes and as COO of


Invalid email.
Get your newsletter about: